Features | Partner Sites | Information | LinkXpress
Sign In
TERARECON, INC.
SCHILLER AG
AMPRONIX

CT Texture Tumor Analysis May Become Useful Biomarker for Localized Esophageal Cancer

By Medimaging International staff writers
Posted on 20 Feb 2013
Computed tomography (CT) texture analysis of primary tumors may become a helpful imaging biomarker in localized esophageal cancer after administering neoadjuvant chemotherapy, according to recent research.

The study’s findings were presented February 9, 2013, at the 2013 Cancer Imaging and Radiation Therapy Symposium, held in Orlando (FL, USA). This symposium is sponsored by the American Society for Radiation Oncology (ASTRO) and the Radiological Society of North American (RSNA).

This study assessed the tumoral texture analysis on baseline and post-treatment CT scans of 31 patients with localized resectable esophageal cancer, with a median age of 63, and who received neoadjuvant chemotherapy between 2007 and 2010. CT scans were performed before and after the use of chemotherapy and before surgery. All patients received fluorouracil-based and platinum chemotherapy followed by surgery. Texture parameters (mean-gray level intensity [MGI], entropy, uniformity, skewness, kurtosis, and standard deviation of histogram [SDH]) were derived for four filter values to highlight structures of different spatial width: 1.0 (fine texture), 1.5–2.0 (medium), and 2.5 (coarse). Median follow-up was 21.9 months. Primary tumors became more homogenous following chemotherapy because entropy decreased and uniformity increased. Smaller change in skewness following chemotherapy was a key prognostic factor—median overall survival was 36.1 months vs. 11.1 months. Lower baseline entropy and lower post-treatment MGI were also tied with increased survival, although they demonstrated only a trend toward significance.

Texture analysis of the CT scans is a post-processing step, which was performed using exclusive software (TexRAD) that enriches the images in ultrafine clarity not visible to the human eye. Specific tumoral characteristics changed consistently following chemotherapy, and some features were linked with overall survival.

“Though these results are for a very small number of patients, they suggest that the tumoral texture features may provide valuable information that could help us to distinguish which patients will do well following chemotherapy and which ones will do poorly,” concluded Connie Yip, MD, the lead study author, a clinical research fellow at King’s College London (UK), and an associate consultant in radiation oncology at the National Cancer Center, Singapore. “As a biomarker for treatment efficacy, this technique could save patients from unnecessary surgery and provide more definitive guidance in developing patient treatment plans with improved outcomes.”

Related Links:

King’s College London




SuperSonic Imagine
RTI ELECTRONICS AB
RADCAL

Channels

MRI

view channel
Image: The quantitative character of the novel 3D technique on MR scans from a patient with primary liver cancer is demonstrated. Images A and B show the scan of the patient before being treated with chemoembolization. The new 3D technique helped quantify the volume and distribution of viable tumor tissue (shown in red and yellow colors). Images C and D demonstrate MR scans acquired after the treatment. The new 3D method helped the radiologists to quantify the vast central destruction of the tumor after the treatment (the dead tumor is represented by the blue color) (Photo courtesy of Johns Hopkins Medicine).

3D MRI Offers Improved Prediction of Survival After Chemotherapy for Liver Tumors

Researchers are using specialized three-dimensional (3D) magnetic resonance imaging (MRI) scanning technology to accurately measure living and dying liver tumor tissue in order to quickly show whether... Read more

Ultrasound

view channel
Image: Siemens Healthcare has launched the HELX Evolution, the newest iteration of its Acuson S range of ultrasound imaging systems (Photo courtesy of Siemens Healthcare).

Ultrasound Imaging System Enhancements Include High Definition Transducers, Sophisticated Elastography, and Tissue Strain Analysis

New features designed for a range of ultrasound systems include enhanced image quality with a large 21.5-inch liquid crystal diode (LCD) monitor, high definition (HD) transducers, optimized contrast agent... Read more

Nuclear medicine

view channel
Image: Sagittal section of brain PET image at four hours after 64CuCl2 injection with disulfiram or D-penicillamine in MD model mice (Photo courtesy of the RIKEN Center for Life Science Technologies).

PET Imaging Used to Assess Effectiveness of Menkes Disease Treatments

Japanese scientists are using positron emission tomography (PET) imaging to visualize the distribution of copper in the body using lab mice. Copper distribution is deregulated in a genetic disorder called... Read more

General/Advanced Imaging

view channel

Secondary Light Emission Generated by Plasmonic Nanostructures May Improve Medical Imaging Technology

New clues into light emission at different wavelengths generated by elements known plasmonic nanostructures may help to improve medical imaging technology. A plasmon is a quantum of plasma oscillation. The plasmon is a quasiparticle resulting from the quantization of plasma oscillations just as photons, and phonons are... Read more

Imaging IT

view channel

Software Designed for the Assessment of Orthopedic Implant Fixation and Bone Segment Motion

Model-based roentgen stereophotogrammetric analysis (MBRSA) software has been developed for evaluation of orthopedic implant fixation and bone segment motion. The software is the first to measure the in vivo three-dimensional (3D) position and/or relative motion of metal implants, markers beads, and/or bone segments in... Read more

Industry News

view channel

Collaboration Expands Capacity for Proton Therapy Clinical Research and Patient Treatments

Varian Medical Systems (Palo Alto, CA, USA) and the Paul Scherrer Institute (PSI; Villigen PSI, Switzerland) are extending an existing collaboration in the field of proton therapy to offer patients more accurate cancer treatments using intensity-modulated proton therapy (IMPT). Under the agreement, Varian will also... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.